Novartis's failed trial for cholesterol drug leads to broad biopharma selloff

Along with several other drugmakers, Novartis has bet that lowering Lp(a) will cut the risk of sometimes fatal cardiovascular events.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。